Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 16.9% in March

Posted by Doug Wharley on Apr 2nd, 2025

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 70,200 shares, a decrease of 16.9% from the February 28th total of 84,500 shares. Currently, 2.6% of the company’s shares are short sold. Based on an average daily volume of 415,800 shares, the short-interest ratio is currently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP purchased a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned approximately 6.13% of Theriva Biologics as of its most recent filing with the SEC. Institutional investors and hedge funds own 6.17% of the company’s stock.

Theriva Biologics Price Performance

TOVX stock traded up $0.06 during mid-day trading on Wednesday, reaching $1.18. The company had a trading volume of 18,775 shares, compared to its average volume of 994,917. The stock has a market cap of $3.28 million, a P/E ratio of -0.04 and a beta of 1.22. The business has a 50 day moving average of $1.37. Theriva Biologics has a 12 month low of $1.03 and a 12 month high of $12.28.

About Theriva Biologics

(Get Free Report)

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.